Header
skip
For US Healthcare Professionals
Jascayd banner

Access for JASCAYD

The CareConnect4MeTM Program can help patients access JASCAYD

Learn about access

Idiopathic pulmonary fibrosis

For the treatment of IPF in adult patients1

Explore IPF data

Progressive pulmonary fibrosis

For the treatment of PPF in adult patients1

Explore PPF data

MOA, mechanism of action; PDE4, phosphodiesterase 4.

INDICATIONS

JASCAYD is indicated for:

  • the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.
  • the treatment of progressive pulmonary fibrosis (PPF) in adult patients.
IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

  • The most common adverse reactions with an incidence of ≥5% in patients treated with JASCAYD were diarrhea, COVID-19, upper respiratory tract infection, depression, weight decreased, decreased appetite, nausea, fatigue, headache, vomiting, back pain, and dizziness.

DRUG INTERACTIONS

Effects of Other Drugs on JASCAYD

  • Strong CYP3A Inhibitors: Reduce the dosage of JASCAYD to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors. Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with a strong CYP3A inhibitor increases exposure of nerandomilast, which may increase the risk of JASCAYD adverse reactions.
  • Moderate or Strong CYP3A Inducers: Avoid use of JASCAYD with strong or moderate CYP3A inducers. Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with moderate or strong CYP3A inducers is expected to decrease exposure of nerandomilast, which may decrease the efficacy of JASCAYD.
  • Pirfenidone: Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with pirfenidone. Do not reduce the dosage to 9 mg twice daily. Concomitant use of JASCAYD with pirfenidone decreases exposure of nerandomilast in patients with IPF. When JASCAYD was used concomitantly with pirfenidone in patients with IPF in FIBRONEER-IPF, efficacy was not observed with the JASCAYD 9 mg twice daily dosage.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Advise pregnant women and females of reproductive potential of the potential risk of fetal loss.
  • Renal Impairment: Use of JASCAYD is not recommended in patients with end stage renal disease (eGFR <15 mL/minute/1.73 m2).
  • Hepatic Impairment: Use of JASCAYD is not recommended in patients with severe (Child-Pugh Class C) hepatic impairment.

CL-JS-100016 12.19.2025

Please see full Prescribing Information for JASCAYD, including Patient Information.

References

  1. JASCAYD® (nerandomilast) Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2026.

  2. Drugs@FDA: FDA-approved drugs. US Food and Drug Administration. Accessed October 8, 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205832

  3. Drugs@FDA: FDA-approved drugs. US Food and Drug Administration. Accessed August 13, 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022535

  4. Pulmonary fibrosis medications. American Lung Association. Updated January 26, 2026. Accessed February 11, 2026. https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-fibrosis/patients/how-is-pulmonary-fibrosis-treated/medications

  5. Raghu G et al. Am J Respir Crit Care Med. 2022;205(9):e18-e47.